文献速递哮喘慢阻肺

成人哮喘与慢阻肺患者嗜酸性粒细胞亚型的差异

Eosinophil Subtypes in Adults with Asthma and Adults with Chronic Obstructive Pulmonary Disease.
PubMed 文献 · Am J Respir Crit Care Med · 2023-01-01

本研究比较了哮喘和慢阻肺患者外周血嗜酸性粒细胞亚型,发现哮喘患者炎症性嗜酸性粒细胞比例显著高于慢阻肺患者、吸烟者和健康人,且炎症性嗜酸性粒细胞表达更多IL-5受体,提示两种疾病嗜酸性粒细胞生物学存在差异。

要点

  • 哮喘患者炎症性嗜酸性粒细胞比例(25±15%)显著高于慢阻肺(0.5±1%)。
  • 炎症性嗜酸性粒细胞IL-5受体表达高于驻留型(P<0.01)。
  • 慢阻肺患者炎症性嗜酸性粒细胞与ICS使用、疾病严重度无关联。

核心结论

  • 哮喘与慢阻肺患者循环嗜酸性粒细胞亚型存在差异,可能影响嗜酸性粒细胞意义的解读和治疗策略。

研究设计与样本

  • 研究纳入四组各10例稳定期受试者:慢阻肺、哮喘、无慢阻肺吸烟者、健康志愿者,哮喘与慢阻肺按年龄、性别和FEV1%预计值匹配。
  • 采用流式细胞术和共聚焦显微镜检测血嗜酸性粒细胞表面蛋白,并在59例慢阻肺和17例哮喘患者中验证。

主要发现

  • 哮喘患者炎症性嗜酸性粒细胞比例为25±15%,高于慢阻肺的0.5±1%、吸烟者的0.14±0.24%和健康人的0.67±1.72%。
  • 哮喘患者炎症性嗜酸性粒细胞比例与总嗜酸性粒细胞数无关。
  • 炎症性嗜酸性粒细胞IL-5受体表达高于驻留型(777.02±124.55 vs. 598.35±318.69;P<0.01)。
  • 慢阻肺患者炎症性嗜酸性粒细胞数量与吸入糖皮质激素使用、疾病严重程度或急性加重率无关。

关键数值与推荐

  • 驻留型嗜酸性粒细胞表型为Siglec-8+CD62L+IL-3Rlo,炎症性嗜酸性粒细胞表型为Siglec-8+CD62LloIL-3Rhi。

临床怎么用

  • 临床解读嗜酸性粒细胞意义时需考虑疾病类型,哮喘患者嗜酸性粒细胞增多可能更多反映炎症性亚型。
  • 靶向IL-5治疗时,哮喘患者可能因炎症性嗜酸性粒细胞高表达IL-5受体而更受益。

局限性

  • 初始研究每组样本量较小(10例),验证队列样本量有限。
  • 仅检测外周血嗜酸性粒细胞,未涉及气道组织。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Rationale: There is a differential response to eosinophilic modulation between patients with asthma and those with chronic obstructive pulmonary disease (COPD). There is also evidence of different subtypes of eosinophils in murine models. However, no study has compared eosinophil subtypes in individuals with COPD and in those with asthma. Objectives: Study the differences in eosinophils subtypes based in the surface protein expression in COPD patients and asthmatic patients. Methods: We studied 10 stable subjects in each of four groups: subjects with COPD, subjects with asthma, smokers without COPD, and healthy volunteers. Subjects with COPD and those with asthma were matched by age, sex, and FEV1% predicted. The following variables were determined: anthropometrics, smoking, exacerbation history, medication use, lung function, and comorbidities. Using flow cytometry and confocal microscopy from blood samples, we determined differences in eosinophil surface proteins and classified them as 1) resident eosinophils (Siglec-8+CD62L+IL-3Rlo) or 2) inflammatory eosinophils (iEos; Siglec-8+CD62LloIL-3Rhi). IL-5 receptor was also determined. Findings were validated in 59 patients with COPD and in 17 patients with asthma. Measurements and Main Results: Patients with asthma had a higher proportion of iEos (25 ± 15%) compared with those with COPD (0.5 ± 1%), smokers without COPD (0.14 ± 0.24%), and healthy volunteers (0.67 ± 1.72%). In patients with asthma, the proportion of iEos was independent of total eosinophil number. iEos had more IL-5 receptors than resident eosinophils (777.02 ± 124.55 vs. 598.35 ± 318.69; P < 0.01). In patients with COPD, there was no relation between iEos number and inhaled corticosteroid use, disease severity, or exacerbations rate. The findings in patients with COPD and those with asthma were confirmed in validation cohorts. Conclusions: There are differences in the subtypes of circulating eosinophils between patients with asthma and those with COPD. This could have clinical implications in the interpretation of eosinophil significance and the approach to therapy in these patients.

来源:Am J Respir Crit Care Med,查看原文。版权归原作者所有。

引用

  1. Cabrera López, Sánchez Santos, Lemes Castellano, et al. Eosinophil Subtypes in Adults with Asthma and Adults with Chronic Obstructive Pulmonary Disease. Am J Respir Crit Care Med. 2023. PMID: 37071848. doi:10.1164/rccm.202301-0149OC

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。